BDRX קצב צמיחת רווח למניה בשנה הנוכחית Biodexa Pharma

Biodexa Pharmaceuticals (BDRX) relies on the Q-Spheres ecosystem for targeted drug delivery. The company's key priority is developing treatments for rare brain tumors that can cross the blood-brain barrier. Patent protection and FDA standards create a significant barrier to entry for competitors. The YoY earnings per share growth rate on GURU.Markets illustrates a trend where 99.50 shows the current value of the metric.

This indicator serves as a key filter during asset stress testing, revealing the actual efficiency of profit generation. The metric measures the daily percentage deviation of current earnings per share from the same period last year, eliminating uncertainty between quarterly reports. By analyzing the annual EPS trend, an investor can assess the monetization potential of Biodexa Pharmaceuticals (BDRX) intellectual property through future royalties from global partners.